Dr. Edward F. Mcclay, M.D.
Medical Oncology (Medical Oncology Physician)
838 Nordahl Rd Ste 300
San Marcos, CA 92069
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 567
Licensed in California since 1988, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: Temple University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license G64594 (first issued 1988; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- California Cancer Associates for Research and Excellence Inc (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 567
- Services billed
- 172,268
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 65,000 | 59 |
| Injection, ferric carboxymaltose, 1 mg | 21,750 | 21 |
| Injection, nivolumab, 1 mg | 19,040 | 15 |
| Injection, pembrolizumab, 1 mg | 19,000 | 19 |
| Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | 6,240 | 12 |
| Injection, denosumab, 1 mg | 6,120 | 35 |
| Injection, aprepitant, 1 mg | 4,420 | 14 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,200 | 36 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,564 | 16 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2,390 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in San Marcos, CA | 51 |
| Hydroxyurea Other prescribers in San Marcos, CA | 23 |
| Prednisone Other prescribers in San Marcos, CA | 22 |
| Levothyroxine Sodium Other prescribers in San Marcos, CA | 20 |
| Ondansetron Odt (ondansetron) Other prescribers in San Marcos, CA | 18 |
| Prochlorperazine Maleate Other prescribers in San Marcos, CA | 16 |
| Anastrozole Other prescribers in San Marcos, CA | 15 |
| Bicalutamide | 14 |
| Hydrocortisone Other prescribers in San Marcos, CA | 13 |
| Revlimid (lenalidomide) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $27.35 in total to this clinician.
| AbbVie Inc. | $27.35 |
|---|
| Food and Beverage | $27.35 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $2,733 in research payments for these studies, mostly to the institutions running them.
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. · Terminated · NCT03906071 - A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.